Clinical efficacy of Hongdoushan capsule combined with chemotherapy on the levels of TSGF,Cyfra21-1,CA125 and CEA for elderly patients with non small cell lung cancer

Objective To study the clinical efficacy of Hongdoushan capsule combined with chemotherapy on the levels of TSGF, Cyfra21-1, CA125 and CEA for elderly patients with non small cell lung cancer. Methods Eighty-four elderly patients with non small cell lung cancer from our hospital were randomly divided into observation group and control group, 42 cases in each group. The control group was treated with GP chemotherapy, while the observation group was treated with Hongdoushan capsule on the base of control group. The effects were observed after the treatment in the two groups. The adverse reactions during the treatment were observed. Before and after treatment, the levels of TSGF, Cyfra21-1, CA125 and CEA in the two groups were detected. Results The total effective rate of the observation group was 83. 33%, which was significantly higher than that of the control group (P < 0. 05). The incidence of adverse reactions in the observation group was lower than that in the control group (P < 0. 05). After treatment, the observation group TSGF, Cyfra21-1, content of CA125 and CEA were (49. 76 ±4. 39) U/ml, (0. 36 ±0. 03) ng/ml, (16. 88 ±1. 38) U/ml and (1. 63 ±0. 36) g/L, were significantly lower than the control group (P < 0. 05). Conclusion Hongdoushan capsule combined with chemotherapy on elderly patients with non small cell lung cancer can improve the clinical efficacy and promote the levels of TSGF, Cyfra21-1, CA125 and CEA of the patients, worth to the next study.